EXACT Sciences (EXAS) Releases Earnings Results, Beats Expectations By $0.09 EPS
EXACT Sciences (NASDAQ:EXAS) posted its quarterly earnings results on Thursday. The medical research company reported ($0.18) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.09, Briefing.com reports. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm had revenue of $87.41 million for the quarter, compared to the consensus estimate of $87.42 million. During the same period in the previous year, the business earned ($0.34) earnings per share. The company’s revenue for the quarter was up 148.0% compared to the same quarter last year.
EXACT Sciences (EXAS) opened at $44.99 on Friday. EXACT Sciences has a 1-year low of $19.91 and a 1-year high of $63.60. The firm has a market capitalization of $5,390.00, a price-to-earnings ratio of -39.12 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.
A number of analysts have commented on EXAS shares. Canaccord Genuity upgraded EXACT Sciences to a “buy” rating and set a $60.00 target price on the stock in a research report on Tuesday, October 31st. Leerink Swann reiterated an “outperform” rating and set a $67.00 target price (up from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. BidaskClub upgraded EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 7th. Benchmark set a $65.00 target price on EXACT Sciences and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Robert W. Baird boosted their target price on EXACT Sciences from $49.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 31st. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $52.84.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/02/22/exact-sciences-exas-announces-earnings-results.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.